Actionable news
All posts from Actionable news
Actionable news in SNY: SANOFI,

Sanofi, Evotec Enter New Research Collaboration

The following excerpt is from the company's SEC filing.

to Discover and Develop Novel Diabetes Therapies

-Collaboration aims to address critical unmet patient need

through next generation diabetes therapies based on stem cell research -

Paris, August 7, 2015

Sanofi announced today that it has entered strategic research collaboration with Evotec to develop beta cell-modulating diabetes treatments, which may reduce or eliminate the need for insulin injections. Beta cells play a key role in the pathogenesis of diabetes, a condition which currently affects 387 million patients worldwide.

With the significant burden of diabetes worl dwide, it is imperative we continue challenging ourselves to develop treatment breakthroughs for the millions of people living with this progressive and debilitating disease,

said Philip Larsen, MD, PhD, Vice President, Global Head of Diabetes Research and Translational Science at Sanofi.

This collaboration will leverage Evotecs expertise in technology and Sanofis extensive experience and leadership in diabetes. Our shared vision is to change how diabetes is treated in the future by developing novel therapeutic approaches to disease management.

The new research collaboration will focus on developing a beta cell replacement therapy based on functional human beta cells derived from human stem cells.

The companies will also use human beta cells for high-throughput drug screening to identify beta cell active small molecules or biologics.

Under this agreement, Evotec will be entitled to receive development, regulatory and commercial milestone payments, which could total more than 300 million, and royalties on net sales.

Stem cell-based drug discovery and development is on the cutting edge of therapeutic innovation,

said Dr. Cord Dohrmann, Chief Scientific Officer of Evotec

. We are very proud to partner with Sanofi, a company with a deep history in diabetes, in a truly complementary collaboration to enhance how this disease is treated in the...